NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

TransCode Therapeutics, Inc. (RNAZ) Stock Analysis

TransCode Therapeutics, Inc. (RNAZ) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RNAZ

$1.66

−$0.02 (−1.19%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RNAZ with… →

RNAZ Key Statistics

As of Oct 21, 2026
Trading
Open
$1.77
Previous Close
$1.68
Day's Range
1.66–1.81
52-Week Range
1.52–13.96
Volume
16.75K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.26
Valuation
Market Cap
$28.11M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−52.06
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$34.66M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
16.93M
1-Year Return
−87.94%
Dividend and dates
Avg Volume
52.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, RNAZ closed at $1.66, −87.94% over 1 year.

TransCode Therapeutics, Inc. (RNAZ) has a market capitalization of $28.11M.

In fiscal 2025, RNAZ reported revenue of $0.00.

RNAZ Stock Return by Calendar Year

TransCode Therapeutics, Inc. (RNAZ) return since Jul 2021: what $10,000 became

1 year
$10,000 $1,206
−87.94%
5 years
$10,000 $0.01
−99.9999%
Since Jul 2021
$10,000 $0.01
−99.9999%

If you had invested $10,000 in TransCode Therapeutics, Inc. (RNAZ) at the close on July 8, 2021, the earliest close on record here, it would have been worth $0.01 at the close on October 21, 2026: −99.9999% in total, −93.43% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−75.70%
2025−92.76%
2024−98.45%
2023−98.77%
2022−73.50%
2021 (partial year)−36.50%

As of October 21, 2026.

RNAZ Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$34.66M—
2024$0.00−$16.75M—
2023$0.00−$18.55M—
2022$0.00−$17.56M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$17.92M−$34.66M—
2024$0.00—−$15.14M−$16.75M—
2023$0.00—−$18.50M−$18.55M—
2022$0.00—−$17.55M−$17.56M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

TransCode Therapeutics, Inc. (RNAZ) is capitalised at $28.11M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 12 employees.

RNAZ last closed at $1.66 on October 21, 2026. That is −$0.02 (−1.19%) against the previous close. The 52-week range on file runs from $1.52 to $13.96. The latest close sits 9.21% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $34.66M. Trailing earnings per share are −52.06.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at 1.26. Daily returns over the trailing 5 years annualize to a volatility of 205.41%. The trailing one-year total return is −87.94%. Measured over 5 years, that is −93.98% a year compounded.

Growth & Income

No dividend is on file for RNAZ.

So far in 2026 the total return is −75.70%. The strongest complete calendar year on file is 2022 at −73.50%; the weakest is 2023 at −98.77%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

TransCode Therapeutics, Inc. (RNAZ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TransCode Therapeutics, Inc. RNAZ $28.11M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. TransCode Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Visit website →